OCULAR THERAPEUTIX SHARES UP 12.7% PREMARKET AFTER RIVAL EYEPOINT'S EYE DRUG MISSES MAIN GOAL IN LATE-STAGE TRIAL

Reuters · 3d ago

Please log in to view news